rpl2802 Antibody

What is RPL2802 and how does it relate to the ribosomal protein family?

RPL2802 appears to be related to the ribosomal protein L22 (RPL22) family, which includes critical components of the large ribosomal subunit. RPL22 is characterized by a globular domain that sits on the surface of the large ribosomal subunit and contains an extended loop that penetrates its core. These structural elements contact multiple domains of 23S rRNA, suggesting a potential role in rRNA folding during ribosomal assembly, though research indicates this role is not essential for function in all contexts .

The protein is also known as heparin-binding protein HBp15 due to its ability to bind heparin in the submandibular gland and brain. Significantly, RPL22 is associated with Epstein-Barr encoded RNAs (EBERs), which are abundantly produced in B lymphocytes infected with Epstein-Barr virus (EBV) .

What are the primary cellular localizations of RPL2802/RPL22 protein?

Immunofluorescence studies using formaldehyde-fixed cells reveal that RPL22 demonstrates a characteristic ribosomal distribution pattern with both cytoplasmic and nucleolar localization. The nucleolar localization typically corresponds to DAPI staining-free regions in the nucleus. Co-immunofluorescence experiments comparing RPL22 with histone H1 show almost specular localization patterns: while RPL22 localizes to the cytoplasm and nucleolus, H1 is positioned exclusively in the nucleus with a staining-free region corresponding to the nucleolar volume occupied by RPL22 .

This dual localization pattern is consistent with the protein's role in ribosome biogenesis (nucleolar presence) and protein synthesis (cytoplasmic presence).

What pathways and biological processes involve RPL2802/RPL22?

Based on pathway analysis, RPL22-related proteins participate in numerous critical cellular processes:

Additionally, RPL22 has been linked to disease processes, with over 120 publications connecting it to neoplasms and over 74 publications associating it with lymphoma .

What are the validated applications for RPL2802/RPL22 antibody in research settings?

The primary validated application for RPL22 antibody is Western Blot (WB) analysis. Recommended dilution ranges for Western Blot applications are 1:500-1:1000 . The antibody has been successfully used to detect RPL22 in various cell types including:

• CT26 whole cell lysate

• Myla2059 whole cell lysate

• A2780 whole cell lysate

Beyond Western Blot, researchers have successfully employed RPL22 antibodies in immunofluorescence (IF) and immunocytochemistry (ICC) experiments to visualize protein localization in fixed cells and tissues .

How should researchers prepare and validate anti-RPL22 antibodies for experimental use?

Production and validation of anti-RPL22 antibodies involve several methodological steps:

• Protein preparation: Express the RPL22/H5 polypeptide in BL21 bacterial cells and isolate using SDS-PAGE. After electrophoresis, visualize the band with light Coomassie Brilliant Blue R-250 staining (0.05%) and excise it with a scalpel .

• Antigen preparation for immunization: Process the excised gel band by fragmenting it into small pieces to enhance phagocytosis and immunological presentation. This can be accomplished by passing the gel fragment between two 5-mL syringes multiple times, followed by further fragmentation using 21-gauge needles .

• Antibody production: Send the prepared antigen to specialized services for polyclonal antibody production in rabbits or other suitable host animals .

• Validation steps:

  • Confirm specificity by comparing signals with pre-immune serum (which should produce no signal)

  • Validate subcellular localization through co-immunostaining with established markers (e.g., fibrillarin for nucleoli, other ribosomal proteins)

  • Test cross-reactivity against related ribosomal proteins to ensure specificity

  • Perform peptide competition assays to confirm binding specificity

What immunofluorescence protocols are optimal for detecting RPL2802/RPL22 in different cell types?

Based on established protocols for RPL22 detection:

• Cell fixation and permeabilization:

  • Fix cells with 4% paraformaldehyde (PFA) for 10 minutes at room temperature

  • Permeabilize with 0.2% Triton X-100

  • Wash thoroughly with PBS

• Blocking and primary antibody incubation:

  • Block non-specific binding with 10% goat serum in PBS for 1 hour

  • Incubate with anti-RPL22 antibody for 1 hour at room temperature

  • Wash three times with PBS

• Secondary antibody and counterstaining:

  • Incubate with appropriate secondary antibody (e.g., Alexa Fluor 488 goat anti-rabbit) at 1:200 dilution for 1 hour

  • Counterstain nuclei with DAPI

  • Mount and visualize using fluorescence microscopy

For co-localization studies, researchers should include markers such as anti-fibrillarin for nucleoli, anti-RPL28 for comparison with other ribosomal proteins, or anti-histone H1 for nuclear distribution patterns .

How does RPL2802/RPL22 interact with nucleic acids and what methods best characterize these interactions?

RPL22 has been demonstrated to bind both RNA and DNA. In particular, DmRpL22 (Drosophila melanogaster RPL22) has been shown to directly and specifically bind DNA . To characterize these interactions, researchers can employ:

• Gel mobility shift assays: These can detect direct interactions between purified RPL22 protein and nucleic acid fragments. Comparing binding to specific sequences versus non-specific controls (like sonicated λ-DNA) helps determine specificity .

• Chromatin immunoprecipitation (ChIP): For investigating in vivo DNA interactions within cellular contexts.

• RNA immunoprecipitation (RIP): Particularly valuable for studying associations with Epstein-Barr encoded RNAs (EBERs) or other RNA species.

• Structural studies: To determine the precise binding domains and conformational changes associated with nucleic acid binding.

The dual RNA/DNA binding capacity of RPL22 suggests potential roles beyond conventional ribosomal functions, possibly including gene expression regulation.

What is the significance of RPL22's association with Epstein-Barr virus RNAs and how can researchers investigate this interaction?

RPL22's association with Epstein-Barr encoded RNAs (EBERs), which are abundantly synthesized in EBV-infected B lymphocytes , represents a fascinating area for investigation. This interaction may have implications for viral pathogenesis and cellular responses to infection.

Methodological approaches to investigate this association include:

• Co-immunoprecipitation assays: Using anti-RPL22 antibodies to pull down RNP complexes, followed by detection of EBER RNAs.

• In situ hybridization combined with immunofluorescence: To visualize co-localization of RPL22 and EBERs within cellular compartments.

• Competitive binding assays: To determine whether EBER binding affects RPL22's ribosomal functions or interactions with other cellular components.

• Functional studies: Using RPL22 knockdown or mutation to assess effects on EBER stability, localization, or function in EBV-infected cells.

Understanding this interaction could provide insights into mechanisms of EBV persistence and pathogenesis, potentially revealing new therapeutic targets for EBV-associated diseases.

How can researchers differentiate between the ribosomal and extra-ribosomal functions of RPL2802/RPL22 using antibody-based approaches?

Distinguishing between canonical ribosomal and non-canonical extra-ribosomal functions requires sophisticated experimental designs:

• Subcellular fractionation combined with immunoblotting: Separate nucleolar, nucleoplasmic, and cytoplasmic fractions to quantify relative distributions across compartments.

• Proximity labeling approaches: Fuse RPL22 with biotin ligases (BioID) or peroxidases (APEX) to identify proximal interaction partners in different cellular compartments.

• Immunoprecipitation with size fractionation: Determine whether RPL22 exists in both ribosome-associated and free pools by comparing immunoprecipitates from different size fractions.

• Conditional depletion with compartment-specific readouts: Assess effects of RPL22 depletion on ribosome biogenesis, translation efficiency, and potential extra-ribosomal processes separately.

• Domain-specific antibodies: Develop antibodies targeting different structural domains of RPL22 to determine which regions are accessible in different functional contexts.

What are common sources of non-specific binding when using RPL2802/RPL22 antibodies and how can they be minimized?

Non-specific binding can significantly compromise experimental outcomes. Common sources and mitigation strategies include:

Always include appropriate negative controls such as pre-immune serum to establish baseline non-specific binding . Testing validation controls under identical experimental conditions to your samples is essential for accurate interpretation.

How should researchers interpret discrepancies between RPL2802/RPL22 antibody data and other detection methods?

When facing inconsistencies between antibody-based detection and other methods (e.g., RNA-seq, mass spectrometry), consider the following analytical framework:

• Method-specific limitations: Antibodies detect protein presence but not necessarily functionality; RNA detection indicates expression but not translation or stability.

• Epitope accessibility: Protein interactions, post-translational modifications, or conformational changes may mask epitopes in certain contexts.

• Threshold differences: Different techniques have varying detection thresholds and dynamic ranges.

• Temporal considerations: mRNA and protein levels may be temporally offset due to synthesis, processing, and degradation kinetics.

• Isoform specificity: Ensure all methods are detecting the same protein isoform or variant.

Resolving discrepancies often requires triangulation using orthogonal methods, such as combining antibody-based detection with fluorescent protein tagging and mass spectrometry.

How are new antibody technologies enhancing RPL2802/RPL22 research?

Recent developments in antibody technology are expanding research capabilities:

• Single-domain antibodies (nanobodies): These smaller antibody fragments can access epitopes that conventional antibodies cannot reach, potentially revealing new aspects of RPL22 structure and interactions.

• Bi-specific antibodies: Allow simultaneous detection of RPL22 and interaction partners, enabling more sophisticated co-localization studies.

• Conformation-specific antibodies: Can distinguish between different functional states of RPL22, providing insights into activity regulation.

• Intrabodies: Expressed within cells to track or functionally perturb RPL22 in specific compartments.

• Recombinant antibody engineering: Enables precise epitope targeting and reduced background through enhanced specificity.

These technologies could help resolve longstanding questions about RPL22's extra-ribosomal functions and regulatory mechanisms.

What methodological approaches can researchers use to study the role of RPL2802/RPL22 in disease contexts?

The association of RPL22 with neoplasms and lymphoma highlights its potential pathological relevance. Investigating these connections requires specialized approaches:

• Tissue microarray immunohistochemistry: Compare RPL22 expression and localization across normal and pathological samples.

• Patient-derived models: Use antibodies to characterize RPL22 status in patient-derived xenografts or organoids.

• Multi-parameter flow cytometry: Combine RPL22 antibodies with markers of cell state to identify correlations with disease progression.

• Mutation-specific antibodies: Develop tools to specifically detect disease-associated RPL22 variants.

• Therapeutic targeting validation: Use antibodies to confirm target engagement in preclinical models of RPL22-associated pathologies.

• Antibody-based proximity proteomics: Map changes in the RPL22 interactome during disease progression.

Understanding these disease connections could potentially reveal new biomarkers or therapeutic targets for conditions including lymphoma and other neoplasms .